Precision BioSciences Inc (DTIL) stock
DTILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends May 21
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 4/3060% above fair value
$7.05−0.23 (-3.16%)
Close on Nov 17, 2026Market cap $194.59MP/E –Yield –
Precision BioSciences operating margin
Operating margin is operating income as a percentage of revenue.
Precision BioSciences's operating margin for the twelve months ending Jun 30, 2026 was -80.8%. For fiscal 2025 it was -152.2%, against -38.1% the year before. The highest annual figure on record is -34.1% in fiscal 2021.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -152.2% | −114.1 |
| FY2024 | Dec 31, 2024 | -38.1% | +51.7 |
| FY2023 | Dec 31, 2023 | -89.8% | +158.5 |
| FY2022 | Dec 31, 2022 | -248.3% | −214.2 |
| FY2021 | Dec 31, 2021 | -34.1% | +418.2 |
| FY2020 | Dec 31, 2020 | -452.2% | −60.1 |
| FY2019 | Dec 31, 2019 | -392.1% | +48.1 |
| FY2018 | Dec 31, 2018 | -440.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -83.7% | +76164.5 |
| Q4 FY2025 | Dec 31, 2025 | 36.6% | +3930.9 |
| Q3 FY2025 | Sep 30, 2025 | -158976.9% | −155283.3 |
| Q2 FY2025 | Jun 30, 2025 | -121538.9% | −121587.3 |
| Q1 FY2025 | Mar 31, 2025 | -76248.3% | −76224.5 |
| Q4 FY2024 | Dec 31, 2024 | -3894.4% | −3682.8 |
| Q3 FY2024 | Sep 30, 2024 | -3693.6% | −3599.3 |
| Q2 FY2024 | Jun 30, 2024 | 48.4% | +64.2 |
| Q1 FY2024 | Mar 31, 2024 | -23.8% | +128.3 |
| Q4 FY2023 | Dec 31, 2023 | -211.6% | −97.3 |
| Q3 FY2023 | Sep 30, 2023 | -94.2% | +105.1 |
| Q2 FY2023 | Jun 30, 2023 | -15.8% | +757.9 |
| Q1 FY2023 | Mar 31, 2023 | -152.1% | +672.0 |
| Q4 FY2022 | Dec 31, 2022 | -114.3% | +370.4 |
| Q3 FY2022 | Sep 30, 2022 | -199.3% | −151.3 |
| Q2 FY2022 | Jun 30, 2022 | -773.7% | −805.1 |
| Q1 FY2022 | Mar 31, 2022 | -824.1% | −709.5 |
| Q4 FY2021 | Dec 31, 2021 | -484.7% | −219.3 |
| Q3 FY2021 | Sep 30, 2021 | -48.0% | +305.7 |
| Q2 FY2021 | Jun 30, 2021 | 31.4% | +3074.9 |
| Q1 FY2021 | Mar 31, 2021 | -114.6% | +278.3 |
| Q4 FY2020 | Dec 31, 2020 | -265.4% | +69.8 |
| Q3 FY2020 | Sep 30, 2020 | -353.7% | +98.0 |
| Q2 FY2020 | Jun 30, 2020 | -3043.4% | −2600.5 |
| Q1 FY2020 | Mar 31, 2020 | -392.9% | −36.0 |
| Q4 FY2019 | Dec 31, 2019 | -335.2% | −9.2 |
| Q3 FY2019 | Sep 30, 2019 | -451.8% | −40.6 |
| Q2 FY2019 | Jun 30, 2019 | -443.0% | +204.1 |
| Q1 FY2019 | Mar 31, 2019 | -356.9% | +247.5 |
| Q4 FY2018 | Dec 31, 2018 | -326.0% | – |
| Q3 FY2018 | Sep 30, 2018 | -411.1% | – |
| Q2 FY2018 | Jun 30, 2018 | -647.0% | – |
| Q1 FY2018 | Mar 31, 2018 | -604.4% | – |
See a number that looks wrong?